Valsartan

also known as Diovan · VAL · VAL489 · CGP 48933 · D763 · D764 · Diovan (Valsartan) · Diovan is a brand name of Valsartan · +18 more

Small molecule targets AGTR1 via inhibition

Developed for: hypertensive disorder · essential hypertension · type 2 diabetes mellitus · hyperlipidemia · heart failure · diabetic kidney disease · proteinuria · cardiovascular disorder
+55 more
· chronic kidney disease · diastolic heart failure · atrial fibrillation · congestive heart failure · COVID-19 · hypertensive heart disease · metabolic syndrome X · stroke disorder · heart disorder · HIV infectious disease · ischemic disease · ischemic stroke · myocardial infarction · pulmonary arterial hypertension · symptomatic heart failure · systolic heart failure · abdominal aortic aneurysm · acute coronary syndrome · adult acute respiratory distress syndrome · Alport syndrome · aortic valve stenosis · atherosclerosis · atherosclerotic cardiovascular disease · chemotherapy-induced toxicity · chronic obstructive pulmonary disease · chronic transplant rejection · cognitive disorder · coronary artery disorder · coronary microvascular disorder · dilated cardiomyopathy · glucose intolerance · hyperlipidemia, combined, 2 · hypertensive nephropathy · IgA glomerulonephritis · impaired renal function disease · kidney disorder · major depressive disorder · mitral valve insufficiency · non-Hodgkin lymphoma · obesity disorder · pneumonia · prediabetes syndrome · ST-elevation myocardial infarction · carotid artery disorder · disorder of defective peroxisome oxidative status · focal segmental glomerulosclerosis · hypertrophic cardiomyopathy · immunoglobulin A vasculitis · intracerebral hemorrhage · left ventricular failure · membranous glomerulonephritis · myocardial disorder · nephrosclerosis · resistant hypertension · Tako-tsubo cardiomyopathy
Investigated by: Novartis · Novartis Pharmaceuticals · Boehringer Ingelheim · LG Life Sciences · IlDong Pharmaceutical Co Ltd · Damanhour University
+155 more
· HK inno.N Corporation · Mario Negri Institute for Pharmacological Research · St. Marianna University School of Medicine · Tehran University of Medical Sciences · AJU Pharm Co., Ltd. · Agenzia Italiana del Farmaco · Asan Medical Center · Forest Laboratories · JW Pharmaceutical · Kitasato University · Medical University of Silesia · Myopharm Limited · National Cheng-Kung University Hospital · National Heart, Lung, and Blood Institute (NHLBI) · Radboud University Medical Center · Shanghai Pharmaceuticals Holding Co., Ltd · Shiraz University of Medical Sciences · Stanford University · Tokai University · University Medical Centre Ljubljana · Yuhan Corporation · ARKAY Therapeutics · Ain Shams University · Albany Medical College · Assaf-Harofeh Medical Center · Assistance Publique - Hôpitaux de Paris · Astellas Pharma Inc · Australian and New Zealand Intensive Care Research Centre · Baker Heart and Diabetes Institute · Bayer · Berry Consultants · Bio-innova Co., Ltd · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Canadian Institutes of Health Research (CIHR) · CardioVascular Research Foundation · Chengdu First People's Hospital · Chinese PLA General Hospital · Chipscreen Biosciences, Ltd. · Chong Kun Dang Pharmaceutical · Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań · Daiichi Sankyo · Danish Cardiovascular Research Academy · Danish Heart Foundation · Dazhou Central Hospital · Dong-A ST Co., Ltd. · Dong-A University · EMS · Farma de Colombia SA · Federico II University · Fifth Affiliated Hospital, Sun Yat-Sen University · Flinders University · Fondation IUCPQ · GlaxoSmithKline · Global Coalition for Adaptive Research · Golestan University of Medical sciences · Gruppo di Ricerca GISSI · Guan'an People's Hospital · Gulhane School of Medicine · Göteborg University · Hallym University Medical Center · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · HeartDrug Research LLC · Hospital Aristide Le Dantec, Dakar, Senegal · Hospital Britanico · Hospital Moinhos de Vento · Hospital do Coracao · Institute of Cardiology Abidjan · Intensive Care National Audit & Research Centre · Intermountain Health Care, Inc. · Isfahan University of Medical Sciences · Jiangsu HengRui Medicine Co., Ltd. · Jikei University School of Medicine · Johns Hopkins University · Jonathan Beaudoin · all 161 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (5)	US (FDA)	DIOVAN	—	2002-04-05 – 2021-04-19	fda.gov ↗
Approved	EU (EMA)	Dafiro	—	2007-01-15	europa.eu ↗
Approved	US (FDA)	DIOVAN	—	1996-12-23	fda.gov ↗

Trials 227 · started per year

today

US approved 1996

EU approved 2007

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 128 trials
Phase 1	NCT07544888	Nov 2025 → Mar 2026	heart disorder, hypertensive disorder	Shaikh Zayed Hospital, Lahore	Completed	No outcome recorded
Phase 1	NCT07331389	Sep 2025 → Jan 2026 overdue	—	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 1	NCT06248112	May → Jun 2024	—	Bio-innova Co., Ltd	Unknown	No outcome recorded
Phase 1	NCT05681273	Feb → Mar 2023	type 2 diabetes mellitus	Chipscreen Biosciences, Ltd.	Completed	No outcome recorded
Phase 1	NCT05259020	Feb → Mar 2022	hyperlipidemia, hypertensive disorder	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 1	NCT05077475	Sep 2021 → Apr 2022	hypertensive disorder	AJU Pharm Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT05077462	Sep 2021 → Apr 2022	hypertensive disorder	AJU Pharm Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT04859452	May → Jul 2021	—	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04185090	Feb → Apr 2020	hyperlipidemia, hypertensive disorder	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 1	NCT03532854	May → Aug 2018	—	LG Chem	Completed	No outcome recorded
Phase 1	NCT02817217	Mar → Jul 2016	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02631031	Nov 2015 → Oct 2016	—	Ain Shams University	Completed	No outcome recorded
Phase 1	NCT02060019	Mar → Jun 2014	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT02069821	Mar 2014	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT01838967	Apr → Jun 2013	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT01918358	Dec 2012 → Jan 2013	hyperlipidemia, hypertensive disorder	LG Life Sciences	Completed	No outcome recorded
Phase 1	NCT01735890	Sep → Nov 2012	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT01823913	Jul → Aug 2012	—	Severance Hospital	Completed	No outcome recorded
Phase 1	NCT01609907	Nov 2011 → May 2012	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT01918709	Sep → Nov 2011	hyperlipidemia	LG Life Sciences	Completed	No outcome recorded
Phase 1	NCT01447485	Aug → Oct 2011	chronic kidney disease, essential hypertension, nephrotic syndrome	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01232049	Oct 2010 → Mar 2011	—	Asan Medical Center	Completed	No outcome recorded
Phase 1	NCT01115972	Mar → Apr 2010	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT02966665	Sep 2008 → Aug 2026 overdue	chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension	Russell Richardson	Recruiting	No outcome recorded
Phase 1	NCT00416728	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00416468	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00415883	Jul 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00310778	Mar 2006 → Mar 2007	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT03686657	Dec 2026 → Dec 2030	arthritic joint disease, hypertensive disorder, obesity disorder, type 2 diabetes mellitus	ARKAY Therapeutics	Withdrawn	No outcome recorded
Phase 1/2	NCT05194111	Aug 2022 → Nov 2028 expected	heart failure	Virginia Commonwealth University	Recruiting	No outcome recorded
Phase 213 trials
Phase 2	NCT07139405	Sep 2026 → Sep 2027 expected	type 2 diabetes mellitus	Myopharm Limited	Not yet recruiting	No outcome recorded
Phase 2	NCT06053580	Feb 2024 → Jul 2027 expected	heart failure, pulmonary arterial hypertension	University of Washington	Recruiting	No outcome recorded
Phase 2	NCT05593575	Mar 2023 → Dec 2024	diabetic kidney disease	Shanghai Pharmaceuticals Holding Co., Ltd	Completed	No outcome recorded
Phase 2	NCT04055428	Aug 2020 → Dec 2026 expected	cardiovascular disorder, diabetes mellitus	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 2	NCT04164732	Jan 2020 → Aug 2023	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01681576	Aug 2012 → Oct 2013	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01353508	Mar 2011 → Aug 2012	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01281306	Jan → Dec 2011	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01122251	Dec 2009 → May 2010	essential hypertension	LG Life Sciences	Completed	No outcome recorded
Phase 2	NCT00939588	Jul → Dec 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00409578	Feb 2007 → Apr 2009	acute coronary syndrome	Novartis	Completed	No outcome recorded
Phase 2	NCT00294086	Dec 2005 → Jan 2007	heart failure	Novartis	Completed	No outcome recorded
Phase 2	NCT00309257	Jan 2004 → Jun 2008	Alport syndrome	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT07539298	May 2026 → May 2029 expected	mitral valve insufficiency	Jonathan Beaudoin	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03315832	Jan 2023 → Jul 2025	aortic valve stenosis, cardiac valvular defect	University Hospital, Limoges	Withdrawn	No outcome recorded
Phase 2/3	NCT00425373	Nov 2006 → Mar 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 374 trials
Phase 3	NCT06930885	Jun 2025 → May 2031 expected	atherosclerotic cardiovascular disease	Hospital do Coracao	Recruiting	No outcome recorded
Phase 3	NCT06863987	Feb 2025 → Dec 2027 expected	essential hypertension	Shandong New Time Pharmaceutical Co., LTD	Enrolling by invitation	No outcome recorded
Phase 3	NCT06643819	Oct 2024 → Mar 2026 overdue	essential hypertension	Chong Kun Dang Pharmaceutical	Recruiting	No outcome recorded
Phase 3	NCT05155137	Dec 2021 → Dec 2029 expected	cognitive disorder, stroke disorder	Hospital Moinhos de Vento	Recruiting	No outcome recorded
Phase 3	NCT05359068	Jun 2021 → Dec 2023	essential hypertension	Shanghai Pharmaceuticals Holding Co., Ltd	Completed	No outcome recorded
Phase 3	NCT04591210	Jan 2021 → Dec 2024	COVID-19, cardiovascular disorder	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT04606563	Oct 2020 → Apr 2022	COVID-19	University of British Columbia	Terminated	No outcome recorded
Phase 3	NCT04128891	Feb 2020	diastolic heart failure	Flinders University	Withdrawn	No outcome recorded
Phase 3	NCT02662894	Oct 2019 → Sep 2020	hyperlipidemia, hypertensive disorder	EMS	Withdrawn	No outcome recorded
Phase 3	NCT03541109	May 2019 → Aug 2023	ST-elevation myocardial infarction	Isfahan University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT03552575	Jul 2018 → Jul 2020	heart failure	NHS Greater Glasgow and Clyde	Completed	No outcome recorded
Phase 3	NCT03508739	Jun 2018 → Jun 2026	hypertensive disorder, prediabetes syndrome, type 2 diabetes mellitus	University of Pennsylvania	Suspended	No outcome recorded
Phase 3	NCT03066804	Aug 2017 → Oct 2019	diastolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	No outcome recorded
Phase 3	NCT03459560	Dec 2015 → Mar 2022	cardiovascular disorder	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT02480764	Aug 2015 → Sep 2017	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT02145104	Jun 2014 → Jun 2016	essential hypertension	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 3	NCT01850160	Apr 2013 → Mar 2015	hypertensive disorder	Farma de Colombia SA	Completed	No outcome recorded
Phase 3	NCT01617681	Nov 2012 → Jan 2017	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01928628	May 2012 → Apr 2013	essential hypertension	LG Life Sciences	Completed	No outcome recorded
Phase 3	NCT01918332	Apr 2012 → Mar 2013	hyperlipidemia, hypertensive disorder	LG Life Sciences	Completed	No outcome recorded
Phase 3	NCT01508026	Jan 2012 → Mar 2013	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT01245608	Oct 2011 → Jan 2018	cardiovascular disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01415505	Aug 2011 → Jan 2013	essential hypertension	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT01365481	Aug 2011 → Sep 2015	chronic kidney disease, hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01402843	Jun 2011 → Jun 2012	hyperlipidemia, hypertensive disorder	JW Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01001572	Sep 2009 → May 2010	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00699192	May 2008 → May 2009	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00548067	Sep 2007 → Mar 2008	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00446511	Jun 2007 → Jun 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00503152	May 2007 → Jul 2016	type 2 diabetes mellitus	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 3	NCT00494715	May 2007 → Apr 2016	type 2 diabetes mellitus	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 3	NCT00457626	Apr 2007 → May 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00446563	Mar 2007 → Mar 2010	hypertensive heart disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00435162	Mar 2007 → Jan 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00446524	Feb 2007 → Oct 2008	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00413049	Jan → Nov 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00437645	Jan → Nov 2007	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00433836	Jan 2007 → Feb 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00386607	Oct 2006 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00392262	Aug 2006 → Feb 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00360178	Jul → Dec 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00350168	Jun 2006 → Apr 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00353912	Jun 2006 → Apr 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00338936	May 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00327587	May 2006 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00327145	Mar 2006 → Jan 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00311740	Mar → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00367939	Dec 2005 → Jul 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00396656	Dec 2005 → Dec 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00273299	Nov 2005 → Jul 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00254475	Nov 2005 → Sep 2006	essential hypertension, hyperlipoproteinemia	Novartis	Completed	No outcome recorded
Phase 3	NCT00394745	Nov 2005 → Jun 2007	essential hypertension, metabolic syndrome X	Novartis	Completed	No outcome recorded
Phase 3	NCT00171015	Dec 2004 → Apr 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00376272	Nov 2004 → Jan 2008	atrial fibrillation	Gruppo di Ricerca GISSI	Completed	No outcome recorded
Phase 3	NCT00171002	Nov 2004 → Jun 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00170963	Oct 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171535	Oct 2004 → Apr 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00170989	Sep 2004 → Jul 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171093	Sep 2004 → Jan 2006	essential hypertension, hyperlipidemia	Novartis	Completed	No outcome recorded
Phase 3	NCT00171067	Jul 2004 → May 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171080	Apr 2004 → Mar 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00170976	Apr 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00409643	Jan → Jul 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00241007	Dec 2003 → Mar 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171028	Dec 2003 → Nov 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00241137	Sep 2003 → Jan 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00409851	Apr 2003 → Mar 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00409760	Jan 2003 → Feb 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171041	Dec 2002 → Mar 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00308425	Oct 2002 → Jun 2005	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00097786	Jan 2002 → Oct 2009	type 2 diabetes mellitus	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00385931	Jan 2002 → Apr 2003	hyperlipidemia, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00089518	—	HIV infectious disease, kidney disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Phase 495 trials
Phase 4	NCT06501651	Aug 2024 → Apr 2025 overdue	diabetic kidney disease, essential hypertension, type 2 diabetes mellitus	Sichuan Academy of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 4	NCT06035978	Mar 2024 → Apr 2026	symptomatic heart failure	University Hospital Ostrava	Unknown	No outcome recorded
Phase 4	NCT05528419	Feb 2023 → Jan 2026	atrial fibrillation, hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT05487261	Dec 2022 → Feb 2025	heart failure	Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań	Unknown	No outcome recorded
Phase 4	NCT06487949	Dec 2022 → Oct 2023	hypertensive disorder	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT05637853	Oct 2022 → Aug 2024 overdue	symptomatic heart failure	Göteborg University	Active not recruiting	No outcome recorded
Phase 4	NCT05881720	Jan 2022 → Jun 2023	heart failure	Damanhour University	Completed	No outcome recorded
Phase 4	NCT05387967	Jan → Jun 2021	systolic heart failure	National Institute of Cardiovascular Diseases, Pakistan	Completed	No outcome recorded
Phase 4	NCT04335786	Apr 2020 → May 2021	COVID-19, adult acute respiratory distress syndrome, severe acute respiratory syndrome	Radboud University Medical Center	Terminated	No outcome recorded
Phase 4	NCT04769778	Feb 2020 → Jun 2023	chronic transplant rejection	Josep m Cruzado	Unknown	No outcome recorded
Phase 4	NCT03594825	Nov 2018 → Jun 2023	hypertensive nephropathy	Fifth Affiliated Hospital, Sun Yat-Sen University	Unknown	No outcome recorded
Phase 4	NCT04707508	Dec 2017 → Jan 2019	type 2 diabetes mellitus	Nantou Christian Hospital	Completed	No outcome recorded
Phase 4	NCT01805804	Jan 2017 → Jan 2019	—	Medical University of Silesia	Terminated	No outcome recorded
Phase 4	NCT02973035	Dec 2016 → Jan 2020	hypertensive disorder	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT02690974	Mar 2016 → Jun 2017	systolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02817360	Feb 2016 → Dec 2025 overdue	heart disorder, type 2 diabetes mellitus	Martin Huelsmann	Recruiting	No outcome recorded
Phase 4	NCT02433119	Mar 2015 → Sep 2016	hypertensive disorder	Dong-A ST Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT02299310	Nov 2014 → Nov 2015	chronic kidney disease	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 4	NCT02062645	Feb 2014 → Sep 2015	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01904981	Jan 2014 → Apr 2017	abdominal aortic aneurysm	Yonsei University	Completed	No outcome recorded
Phase 4	NCT02058446	Oct 2013 → Mar 2014	essential hypertension	TSH Biopharm Corporation Limited	Completed	No outcome recorded
Phase 4	NCT01699490	Aug 2012 → Jul 2015	major depressive disorder	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT01541189	Feb 2012 → Jan 2013	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01368536	May 2011 → Feb 2012	hypertensive disorder, type 2 diabetes mellitus	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01030458	Sep 2010 → Mar 2012	hypertensive disorder	KU Leuven	Completed	No outcome recorded
Phase 4	NCT01167153	May 2010 → Apr 2011	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01095822	Mar → Dec 2010	diabetes mellitus	HeartDrug Research LLC	Unknown	No outcome recorded
Phase 4	NCT00902304	Jul 2009 → Jul 2011	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00931710	Jul 2009 → Jan 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01070043	Jun 2009 → Sep 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00927394	May 2009 → Oct 2011	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00858299	Mar 2009 → Dec 2011	chronic kidney disease, proteinuria	Samsung Medical Center	Unknown	No outcome recorded
Phase 4	NCT01241487	Feb 2009 → Jan 2011	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00809926	Jan → Jul 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00874601	Oct 2008 → Jul 2011	ischemic stroke	Hallym University Medical Center	Unknown	No outcome recorded
Phase 4	NCT00716950	Jul 2008 → Feb 2009	essential hypertension	University of Pavia	Unknown	No outcome recorded
Phase 4	NCT00698646	Apr 2008 → Jun 2009	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00687206	Mar → May 2008	erectile dysfunction, hypertensive disorder	Federico II University	Completed	No outcome recorded
Phase 4	NCT00921570	Feb 2008 → May 2009	hypertensive disorder, proteinuria, type 2 diabetes mellitus	Gulhane School of Medicine	Completed	No outcome recorded
Phase 4	NCT00687973	Jan 2008 → Jan 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01340326	Nov 2007 → Dec 2014	myocardial infarction	Dong-A University	Completed	No outcome recorded
Phase 4	NCT00700271	Oct 2007 → Aug 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01400256	Aug 2007 → Feb 2009	ischemic stroke	Stanford University	Withdrawn	No outcome recorded
Phase 4	NCT00457483	Aug 2007 → Dec 2010	essential hypertension	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT00550095	Jun 2007 → Nov 2009	proteinuria	Novartis	Completed	No outcome recorded
Phase 4	NCT00439738	Dec 2006 → Nov 2007	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00409487	Dec 2006	hypertensive disorder, obstructive sleep apnea syndrome	University Hospital, Grenoble	Completed	No outcome recorded
Phase 4	NCT00425997	Dec 2006 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00523549	Nov 2006 → Jan 2008	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01425411	Nov 2006 → Nov 2008	hypertensive disorder, hypertensive heart disease	Mustafa Kemal University	Completed	No outcome recorded
Phase 4	NCT00426478	Nov 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00407680	Oct 2006 → Mar 2009	hypertensive disorder, type 2 diabetes mellitus	Kitasato University	Unknown	No outcome recorded
Phase 4	NCT00589732	Sep 2006 → Dec 2009	coronary artery disorder	CardioVascular Research Foundation	Completed	No outcome recorded
Phase 4	NCT00400777	Aug 2006 → Nov 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00460213	Jul 2006 → Dec 2008	hypertensive disorder	Kitakyushu-Tsuyazaki Hospital	Completed	No outcome recorded
Phase 4	NCT00351130	Jun 2006 → Mar 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00304226	Feb 2006 → Jan 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00280540	Dec 2005 → Aug 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00277472	Nov 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00168779	Sep 2005 → Jul 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171600	Jul 2005 → Jan 2007	diabetic kidney disease, hypertensive disorder	Novartis	Terminated	No outcome recorded
Phase 4	NCT00821574	Jul 2005 → Mar 2007	hyperlipidemia, combined, 2	Novartis	Completed	No outcome recorded
Phase 4	NCT01917149	Mar 2005 → Jul 2013	dilated cardiomyopathy	Xijing Hospital	Completed	No outcome recorded
Phase 4	NCT00200694	Mar 2005 → Mar 2007	proteinuria	Nantes University Hospital	Terminated	No outcome recorded
Phase 4	NCT00170937	Nov 2004 → Mar 2006	hypertensive disorder, metabolic syndrome X	Novartis	Completed	No outcome recorded
Phase 4	NCT00171574	Nov 2004 → Jul 2006	diabetic kidney disease, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00185055	Nov 2004 → Feb 2005	—	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00343499	Nov 2004 → Jul 2007	atrial fibrillation	Intermountain Health Care, Inc.	Terminated	No outcome recorded
Phase 4	NCT00170924	Aug 2004 → Jun 2006	diastolic heart failure, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171132	Aug 2004 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171353	Jul 2004 → Sep 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171327	Jul 2004 → Sep 2005	hyperlipidemia, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171756	Jun 2004 → Mar 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00162955	May 2004 → Sep 2010	non-Hodgkin lymphoma	Osaka City University	Completed	No outcome recorded
Phase 4	NCT00241124	Apr 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00333489	Mar 2004 → Apr 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00171782	Feb → Dec 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00149227	Jan 2004 → Jan 2009	congestive heart failure, hypertensive disorder, ischemic disease, stroke disorder	Kyoto Prefectural University of Medicine	Completed	No outcome recorded
Phase 4	NCT00171119	Jan 2004 → Mar 2005	diabetic kidney disease, hypertensive disorder	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT00154271	Jan 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00202618	Dec 2003 → Jun 2006	diabetes mellitus, hypertensive disorder, proteinuria	Shiga University	Unknown	No outcome recorded
Phase 4	NCT00240448	Sep 2003 → Jun 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171054	Sep 2003 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00241098	May 2003 → Jun 2005	congestive heart failure, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00153023	Apr 2003 → Dec 2005	diabetic kidney disease, essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171561	Mar 2003 → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00190580	Feb 2003 → Apr 2008	chronic kidney disease, hypertensive disorder	KVT-Study Group	Completed	No outcome recorded
Phase 4	NCT00239538	Jan 2003 → Dec 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171106	Dec 2002 → Aug 2007	diastolic heart failure	Novartis	Completed	No outcome recorded
Phase 4	NCT00241150	Nov 2002 → Jan 2005	hypertensive disorder, metabolic syndrome X	Novartis	Completed	No outcome recorded
Phase 4	NCT00241085	Nov 2002 → Aug 2005	hypertensive disorder, proteinuria, type 2 diabetes mellitus	Novartis	Completed	No outcome recorded
Phase 4	NCT00241072	Sep 2002 → Jul 2005	glucose intolerance, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00133328	Jan 2002 → Nov 2005	congestive heart failure, hypertensive disorder, ischemic disease	Jikei University School of Medicine	Unknown	No outcome recorded
Phase 4	NCT00034840	Oct 2001 → Aug 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00367562	Jan 1996 → Dec 2005	IgA glomerulonephritis	Hospital Britanico	Completed	No outcome recorded

Phase not applicable12 trials
—	NCT05892146	May 2021 → Dec 2025	breast cancer, chemotherapy-induced toxicity, heart failure, lymphoma	National Cheng-Kung University Hospital	Unknown	No outcome recorded
—	NCT03393377	Sep 2014 → Jun 2015	atherosclerosis	University Medical Centre Ljubljana	Completed	No outcome recorded
—	NCT02606279	Jul 2014 → Aug 2016	HIV infectious disease, muscular atrophy, premature aging syndrome	Wake Forest University Health Sciences	Terminated	No outcome recorded
—	NCT03309618	Nov 2012 → Nov 2013	myocardial infarction	University Medical Centre Ljubljana	Completed	No outcome recorded
—	NCT01767298	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT01767259	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT00732966	Sep 2008 → Sep 2009	hypertensive disorder	Assaf-Harofeh Medical Center	Unknown	No outcome recorded
—	NCT00721773	Sep 2008 → Oct 2014	impaired renal function disease	Sun Yat-sen University	Completed	No outcome recorded
—	NCT00627991	Aug 2007 → ?	stroke disorder	Stanford University	Withdrawn	No outcome recorded
—	NCT00424801	Jan 2007 → Dec 2008	coronary microvascular disorder, essential hypertension	University of Aarhus	Terminated	No outcome recorded
—	NCT00518479	Sep 2003 → Apr 2004	hypertensive disorder, hypertensive heart disease	University of Leeds	Completed	No outcome recorded
—	NCT00530595	—	cardiovascular disorder	Saitama Medical University	Completed	No outcome recorded

Also used as a comparator or background therapy in 132 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04623866 Comparator	Nov 2020 → Aug 2021	immunoglobulin A vasculitis	The Children's Hospital of Zhejiang University School of Medicine	Unknown	No outcome recorded
Phase 114 trials
Phase 1	NCT07444398 Background	Jan → Mar 2026 overdue	symptomatic heart failure	Khawaja Danish Ali	Recruiting	No outcome recorded
Phase 1	NCT04047940 Comparator	Nov 2019 → Feb 2020	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT03012763 Comparator	Apr 2016 → Jan 2017	—	University Medicine Greifswald	Completed	No outcome recorded
Phase 1	NCT03009474 Comparator	Feb → Apr 2015	hyperlipidemia, hypertensive disorder	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT03648333 Comparator	Dec 2013 → Feb 2014	—	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02815657 Comparator	Apr 2013 → Jan 2014	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01819779 Comparator	Mar → May 2013	—	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01764178 Comparator	Jan → Mar 2013	hyperlipidemia, hypertensive disorder	JW Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01652339 Comparator	Jul → Aug 2012	—	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01776047 Comparator	Jul → Sep 2012	—	Dong-A Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01494727 Comparator	Feb → Apr 2012	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT01406431 Comparator	Aug 2011	hyperlipidemia, hypertensive disorder	JW Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01432106 Comparator	Feb 2011 → Dec 2012	hypertensive disorder, metabolic syndrome X	University of Michigan	Withdrawn	No outcome recorded
Phase 1	NCT00839683 Comparator	Feb → Mar 2009	type 2 diabetes mellitus	AstraZeneca	Completed	No outcome recorded

Phase 217 trials
Phase 2	NCT07700875 Comparator	Dec 2022 → Aug 2023	essential hypertension	Wuhan Createrna Science and Technology Co., Ltd	Completed	No outcome recorded
Phase 2	NCT05638880 Background	Dec 2022 → Dec 2025	diabetic kidney disease	Mostafa Bahaa	Completed	No outcome recorded
Phase 2	NCT03928158 Comparator	May 2019 → Jun 2023	essential hypertension, heart failure	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation	Completed	No outcome recorded
Phase 2	NCT03553810 Comparator	Apr 2019 → Jun 2024	hypertensive heart disease	National Heart Centre Singapore	Completed	No outcome recorded
Phase 2	NCT04149990 Comparator	Oct 2018 → Jul 2022	myocardial infarction	Jacob Moller	Terminated	No outcome recorded
Phase 2	NCT03415906 Comparator	Dec 2017 → Sep 2018	heart failure	Hannover Medical School	Withdrawn	No outcome recorded
Phase 2	NCT03005184 Background	Sep 2017 → Jan 2020	mild heart failure, moderate heart failure	Vanderbilt University Medical Center	Withdrawn	No outcome recorded
Phase 2	NCT02966717 Comparator	Aug → Oct 2016	chronic kidney disease, nephrotic syndrome	Zhujiang Hospital	Unknown	No outcome recorded
Phase 2	NCT04687111 Comparator	Dec 2015 → Jun 2021	cardiac rhythm disease, hypertensive disorder, myocardial disorder, myositis disease	Mark Ledwidge	Unknown	No outcome recorded
Phase 2	NCT01912534 Comparator	Mar 2014 → Jul 2019	hypertrophic cardiomyopathy	Carelon Research	Completed	No outcome recorded
Phase 2	NCT01878201 Comparator	May 2013 → Feb 2014	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 2	NCT00887588 Comparator	Nov 2009 → Dec 2011	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00819767 Comparator	Feb → Oct 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 2	NCT00922441 Comparator	Dec 2008 → Aug 2009	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 2	NCT00732069 Comparator	Aug 2008 → Dec 2011	dialysis disequilibrium syndrome, end stage renal failure	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT00549770 Comparator	Sep 2007 → Jul 2008	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00208767 Comparator	Feb 2005 → Nov 2009	atherosclerosis, carotid artery disorder	Emory University	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT04971720 Comparator	Feb 2022 → Jan 2027 expected	hypertensive disorder, obesity disorder	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 328 trials
Phase 3	NCT07356388 Background	Jan 2025 → Oct 2027 expected	disease related to solid organ transplantation, proteinuria	kewen Chen,MD	Active not recruiting	No outcome recorded
Phase 3	NCT06771245 Comparator	Jan 2025 → Mar 2026 overdue	essential hypertension	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT05920005 Comparator	Aug 2023 → Mar 2025	hypertensive disorder	Hospital Israelita Albert Einstein	Completed	No outcome recorded
Phase 3	NCT05545059 Comparator	Sep → Oct 2022	resistant hypertension	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Unknown	No outcome recorded
Phase 3	NCT07116863 Comparator	Jun 2022 → Jun 2024	essential hypertension	Kyungdong Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT04912167 Background	Nov 2021 → Mar 2022	ST-elevation myocardial infarction	West China Hospital	Unknown	No outcome recorded
Phase 3	NCT05056727 Background	Sep 2021 → Feb 2024	chronic kidney disease	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT04686643 Background	Feb 2021 → Feb 2022	hypertensive disorder	Ahn-Gook Pharmaceuticals Co.,Ltd	Unknown	No outcome recorded
Phase 3	NCT03988634 Comparator	Jun 2019 → Dec 2022	diastolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT03639480 Comparator	Oct 2017 → Oct 2018	hyperlipidemia, hypertensive disorder	HK inno.N Corporation	Unknown	No outcome recorded
Phase 3	NCT02924727 Background	Dec 2016 → Feb 2021	acute myocardial infarction	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02884206 Comparator	Nov 2016 → May 2022	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT03536598 Comparator	Oct 2016 → Sep 2017	hyperlipidemia, combined, 2	HK inno.N Corporation	Completed	No outcome recorded
Phase 3	NCT01920711 Comparator	Jul 2014 → Jun 2019	diastolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT05170061 Comparator	Feb 2013 → Sep 2014	hypertensive disorder	State University of New York at Buffalo	Completed	No outcome recorded
Phase 3	NCT01672476 Comparator	Apr 2012 → Mar 2013	hypertensive disorder	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 3	NCT01271985 Comparator	Feb 2011 → Jan 2019	cardiovascular disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT00878969 Comparator	Jan 2010 → Jun 2015	disorder of defective peroxisome oxidative status	Vanderbilt University	Terminated	No outcome recorded
Phase 3	NCT00657241 Comparator	Apr 2008 → Apr 2010	hypertensive disorder	State University of New York at Buffalo	Completed	No outcome recorded
Phase 3	NCT00696436 Comparator	Apr 2008 → Aug 2009	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00738972 Background	Jan 2008 → Aug 2010	hypertensive disorder	Fundación Lindavista del Corazón AC	Terminated	No outcome recorded
Phase 3	NCT00591578 Comparator	Dec 2007 → Sep 2009	hypertensive disorder	Takeda	Completed	No outcome recorded
Phase 3	NCT00546754 Comparator	May 2007 → Apr 2009	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00413413 Comparator	Jan → Nov 2007	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00250562 Background	Oct 2005 → Jun 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00000620 Background	Sep 1999 → Jun 2009	atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT02177396 Comparator	Apr → Dec 1998	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT06395194 Comparator	Sep 1997 → Sep 2003	essential hypertension	Oslo University Hospital	Completed	No outcome recorded

Phase 458 trials
Phase 4	NCT06536309 Comparator	Jul 2026 → Dec 2028 expected	diastolic heart failure	Brigham and Women's Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07547878 Comparator	Apr 2026 → Mar 2029 expected	chronic kidney disease, type 2 diabetes mellitus	Baylor Research Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT07513883 Background	Mar 2026 → Sep 2028 expected	heart failure	Ziekenhuis Oost-Limburg	Recruiting	No outcome recorded
Phase 4	NCT06341101 Background	Mar 2024 → Mar 2026	diastolic heart failure	Maastricht University Medical Center	Unknown	No outcome recorded
Phase 4	NCT05095922 Background	Mar 2023 → May 2024	diabetic peripheral angiopathy, type 2 diabetes mellitus	Affiliated Hospital of Nantong University	Completed	No outcome recorded
Phase 4	NCT05269615 Comparator	Mar 2023 → Sep 2024	—	The University of Hong Kong	Unknown	No outcome recorded
Phase 4	NCT07327749 Comparator	Oct 2022 → Dec 2024	hypertensive disorder	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT05060588 Comparator	Oct 2021 → Oct 2022	hypertensive disorder, myocardial infarction	Qingdao Central Hospital	Unknown	No outcome recorded
Phase 4	NCT04394117 Comparator	Jun 2020 → Nov 2021	COVID-19	The George Institute	Completed	No outcome recorded
Phase 4	NCT04330300 Comparator	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded
Phase 4	NCT03938389 Comparator	Feb 2020 → Feb 2024 overdue	glucose intolerance, hypertensive disorder, obesity disorder, prediabetes syndrome	Ohio State University	Active not recruiting	No outcome recorded
Phase 4	NCT04688294 Comparator	Jan 2020 → May 2021	heart failure	Amir Safwat	Completed	No outcome recorded
Phase 4	NCT03893526 Comparator	Jan 2019 → Mar 2021	type 2 diabetes mellitus	University of Copenhagen	Completed	No outcome recorded
Phase 4	NCT03990480 Comparator	Dec 2018 → Apr 2019	essential hypertension	Damanhour University	Completed	No outcome recorded
Phase 4	NCT03738878 Comparator	Nov 2018 → Dec 2024	hypertensive disorder	Vanderbilt University Medical Center	Terminated	No outcome recorded
Phase 4	NCT03502031 Comparator	Oct 2018 → Oct 2022	diabetic kidney disease	James A. Tumlin, MD	Unknown	No outcome recorded
Phase 4	NCT03476616 Comparator	Sep 2018 → Jun 2025	essential hypertension, obesity disorder	Hippocration General Hospital	Completed	No outcome recorded
Phase 4	NCT03300427 Comparator	Jul 2018 → Mar 2022	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT03717688 Comparator	May 2018 → Feb 2019	diabetes mellitus, heart failure	Nicolai Jacob Wewer Albrechtsen	Completed	No outcome recorded
Phase 4	NCT03279861 Comparator	Nov 2017 → Nov 2018	congestive heart failure, hypertensive disorder	University of Maryland, Baltimore	Withdrawn	No outcome recorded
Phase 4	NCT03168568 Comparator	May 2017 → Sep 2020	heart failure	University of Zurich	Completed	No outcome recorded
Phase 4	NCT02816736 Comparator	Mar 2017 → Sep 2020	heart failure	Duke University	Completed	No outcome recorded
Phase 4	NCT03180593 Comparator	Feb 2017 → Jan 2018	heart disorder, hypertensive disorder	Trinity Hypertension & Metabolic Research Institute	Completed	No outcome recorded
Phase 4	NCT02765594 Background	Jun 2016 → May 2019	IgA glomerulonephritis	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 4	NCT04061824 Comparator	May 2016 → Dec 2018	hyperlipidemia, hypertensive disorder	Yonsei University	Completed	No outcome recorded
Phase 4	NCT02687932 Comparator	Mar 2016 → Jan 2018	left ventricular failure, mitral valve insufficiency	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT02639637 Comparator	Dec 2015 → Jun 2017	type 2 diabetes mellitus	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT02572960 Comparator	Oct 2015 → May 2017	cardiovascular disorder, osteoporosis, vitamin D deficiency	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT02495324 Comparator	Jun 2015 → May 2017	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 4	NCT02200822 Comparator	Jul 2014 → Feb 2019	heart failure	Hasselt University	Completed	No outcome recorded
Phase 4	NCT02058823 Comparator	Aug 2013 → Jul 2014	obstructive sleep apnea syndrome	University Hospital, Grenoble	Terminated	No outcome recorded
Phase 4	NCT01609959 Comparator	Jun 2012 → Sep 2013	hypertensive disorder	Nara Medical University	Completed	No outcome recorded
Phase 4	NCT02403349 Comparator	May 2012 → May 2015	hypertensive disorder, ischemic stroke	Ajou University School of Medicine	Unknown	No outcome recorded
Phase 4	NCT01377285 Background	Jun 2010 → Dec 2018	chronic renal failure syndrome	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT00993109 Comparator	Feb 2010 → May 2011	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT01071122 Comparator	Jan 2010 → Feb 2012	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT01004237 Comparator	Nov 2009 → Apr 2012	hypertensive disorder	Gachon University Gil Medical Center	Completed	No outcome recorded
Phase 4	NCT01129557 Comparator	Sep 2009 → Jan 2012	IgA glomerulonephritis, diabetic kidney disease, focal segmental glomerulosclerosis, membranous glomerulonephritis +2	Columbia University	Terminated	No outcome recorded
Phase 4	NCT01819220 Comparator	Apr 2009 → Nov 2014	hypertensive disorder	Yonsei University	Completed	No outcome recorded
Phase 4	NCT00741585 Comparator	Sep 2008 → Jun 2018	chronic kidney disease, essential hypertension, stroke disorder	University of Vigo	Completed	No outcome recorded
Phase 4	NCT00666536 Comparator	Mar 2008 → Jan 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00599885 Comparator	Sep 2007 → Jul 2008	coronary artery disorder, hypertensive disorder, type 2 diabetes mellitus	Korea University Anam Hospital	Completed	No outcome recorded
Phase 4	NCT00745953 Comparator	Aug 2007 → Aug 2009	metabolic syndrome X	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT00500604 Comparator	Jul 2007 → Jan 2010	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT01375322 Comparator	Jun 2007 → Jun 2010	hypertensive disorder, proteinuria, type 2 diabetes mellitus	TSH Biopharm Corporation Limited	Completed	No outcome recorded
Phase 4	NCT00426348 Background	May 2007 → Jan 2013	IgA glomerulonephritis	Guangdong Provincial People's Hospital	Completed	No outcome recorded
Phase 4	NCT00391846 Background	Oct 2006 → Jan 2009	left ventricular failure	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00140790 Comparator	Aug 2006 → Mar 2015	hypertensive disorder	Kumamoto University	Terminated	No outcome recorded
Phase 4	NCT00790946 Comparator	Jun 2006 → Dec 2009	hypertensive disorder, obesity disorder	Kagoshima University	Unknown	No outcome recorded
Phase 4	NCT00130156 Background	Oct 2005 → Sep 2008	benign essential hypertension	Eisai Inc.	Completed	No outcome recorded
Phase 4	NCT00661895 Background	Aug 2005 → Aug 2009	hypertensive disorder	Creighton University	Completed	No outcome recorded
Phase 4	NCT00302705 Comparator	Jan 2005 → Mar 2007	essential hypertension	University of Vigo	Completed	No outcome recorded
Phase 4	NCT00129233 Comparator	Oct 2004 → Jul 2010	hypertensive disorder, type 2 diabetes mellitus	Nagoya University	Completed	No outcome recorded
Phase 4	NCT00982358 Comparator	Jul 2004 → Oct 2006	coronary artery disorder, hypertensive disorder, type 2 diabetes mellitus	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 4	NCT01518855 Background	Mar 2004 → Apr 2005	essential hypertension	Bayer	Completed	No outcome recorded
Phase 4	NCT02242318 Comparator	Sep 2001 → Sep 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00295542 Comparator	Mar 2000 → Apr 2009	hypertensive disorder	University of Vigo	Completed	No outcome recorded
Phase 4	NCT00487123 Background	? → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded

Phase not applicable13 trials
—	NCT07458880 Comparator	Mar 2026 → Sep 2029 expected	intracerebral hemorrhage	The University of Hong Kong	Recruiting	No outcome recorded
—	NCT07491718 Comparator	Aug 2025 → Aug 2028 expected	Tako-tsubo cardiomyopathy	University of Edinburgh	Recruiting	No outcome recorded
—	NCT07702669 Background	Oct 2023 → Aug 2025	metabolic syndrome X	First Affiliated Hospital of Heilongjiang Chinese Medicine University	Completed	No outcome recorded
—	NCT06344247 Background	Sep 2023 → Sep 2025	chronic kidney disease, obesity disorder	RenJi Hospital	Unknown	No outcome recorded
—	NCT04800081 Comparator	Jul 2020 → Jun 2021	essential hypertension	LanZhou University	Unknown	No outcome recorded
—	NCT04458285 Comparator	Jan → Dec 2020	heart failure	Guangdong Provincial People's Hospital	Unknown	No outcome recorded
—	NCT03791723 Comparator	Jun 2019 → Jan 2021	atrial fibrillation	The Second Affiliated Hospital of Chongqing Medical University	Unknown	No outcome recorded
—	NCT03432468 Comparator	Apr 2018 → Aug 2019	hypertensive disorder	LanZhou University	Unknown	No outcome recorded
—	NCT01252238 Comparator	Jun 2010 → Dec 2012	—	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT00691314 Comparator	Jun 2008 → Sep 2010	atherosclerosis, transient ischemic attack	Peking Union Medical College Hospital	Completed	No outcome recorded
—	NCT00655330 Background	May 2008 → May 2017	diabetic kidney disease, type 2 diabetes mellitus	Guangdong Provincial People's Hospital	Unknown	No outcome recorded
—	NCT00664846 Background	Apr 2008 → Dec 2010	ischemic stroke	Peking Union Medical College Hospital	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2018-08-25	Novartis Pharmaceuticals	Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗
2015-01-06	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches Generic Diovan® in the United States tevapharm.com ↗
2008-06-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval of Generic Diovan® Tablets tevapharm.com ↗

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 367 sources stand behind the page.

Field	Value	Cited text
Known as	valsartan	“Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗ 354 “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily” NCT01271985 ↗ “Fixed-dose combination tablet containing valsartan 160 mg and amlodipine 10 mg. Orally administered once daily for 6 weeks during Treatment Period 2.” NCT07116863 ↗ “500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.” NCT03686657 ↗ “RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)” NCT03502031 ↗ “If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced.” NCT05637853 ↗ “The polypill comprises hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg.” PMID 32894967 ↗ Aug 2020 “Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together” NCT05077462 ↗ “Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg” NCT01245608 ↗ “coadministration of Diovan® (Valsartan) 160 mg and Crestor® (Rosuvastatin) 20 mg in healthy male volunteers” NCT01918358 ↗ “The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan.” NCT04591210 ↗ “Oral ACEI/ARB (e.g., valsartan capsules 80mg qd or 150mg qd) + finelidone (10 or 20mg orally once a day)” NCT07356388 ↗ “fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)” NCT03541109 ↗ “Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks” NCT02433119 ↗ “Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg” NCT03009474 ↗ “combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)” NCT02069821 ↗ “LCZ696 is a novel combination drug consisting of two antihypertensives, sacubitril and valsartan.” NCT04149990 ↗ “inhibition of neprilysin by sacubitril/valsartan alone or in combination with a DPP-4 inhibitor” PMID 31074791 ↗ Sep 2019 “A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg” NCT01823913 ↗ “Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).” NCT02966665 ↗ “Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan” NCT04330300 ↗ “Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug” NCT01918709 ↗ “ARB (second line alternative to ACEi): valsartan, losartan or candesartan” NCT07513883 ↗ “In case of side effects Perindopril will be replaced by Valsartan” NCT06341101 ↗ “V - Valsartan 160mg will be administered orally only one time.” NCT01838967 ↗ “Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)” NCT01776047 ↗ “amlodipine besylate (10mg as amlodipine), valsartan 160mg” NCT03648333 ↗ “valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop” NCT02200822 ↗ “Sacubitril/Valsartan (25/80) mg twice a day for 1 year” NCT05892146 ↗ “Valturna (aliskiren 150 mg/valsartan 160 mg) tablet” NCT01368536 ↗ “C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet” NCT05077475 ↗ “exforge 10/160mg(amlodipine 10mg, valsartan160mg)” NCT02060019 ↗ “or Valsartan 80mg/day or Nifedipine 30mg/day” NCT00691314 ↗ “telmisartan, valsartan, diltiazem, dilacor” NCT00684489 ↗ “valsartan, an angiotensin receptor blocker” PMID 22410289 ↗ Mar 2012 “Valsartan 80mg/day or Nifedipine 30mg/day” NCT00664846 ↗ “S-amlodipine, Valsartan, Indapamide” NCT04686643 ↗ “Amlodipine 10mg/Valsartan 160mg” NCT04185090 ↗ “valsartan (Diovan)” NCT00000620 ↗ “* valsartan 160mg” NCT01819779 ↗ “* valsartan 160mg” NCT01652339 ↗ “Valsartan 320mg/d” NCT02817360 ↗ “Valsartan” NCT02735707 ↗ “Valsartan” NCT00741585 ↗ “valsartan” NCT04164732 ↗ NCT00409851 ↗ NCT00821574 ↗ NCT00819767 ↗ NCT01070043 ↗ NCT02062645 ↗ NCT05095922 ↗ NCT00392262 ↗ NCT01699490 ↗ NCT00391846 ↗ NCT00089518 ↗ NCT03928158 ↗ NCT05359068 ↗ NCT01494727 ↗ NCT01767298 ↗ NCT00277472 ↗ NCT00254475 ↗ NCT01767259 ↗ NCT00333489 ↗ NCT00171353 ↗ NCT00171327 ↗ NCT00732966 ↗ NCT02639637 ↗ NCT00721773 ↗ NCT01122251 ↗ NCT01425411 ↗ NCT00627991 ↗ NCT00386607 ↗ NCT00993109 ↗ NCT02924727 ↗ NCT05259020 ↗ NCT03738878 ↗ NCT00338936 ↗ NCT04688294 ↗ NCT01904981 ↗ NCT00523549 ↗ NCT00133328 ↗ NCT00171132 ↗ NCT00129233 ↗ NCT00439738 ↗ NCT07544888 ↗ NCT01030458 ↗ NCT05638880 ↗ NCT00732069 ↗ NCT00409760 ↗ NCT00202618 ↗ NCT03594825 ↗ NCT00409578 ↗ NCT00500604 ↗ NCT02884206 ↗ NCT00149227 ↗ NCT04912167 ↗ NCT02480764 ↗ NCT00171119 ↗ NCT00168779 ↗ NCT06771245 ↗ NCT01375322 ↗ NCT02973035 ↗ NCT00745953 ↗ NCT07444398 ↗ NCT00409643 ↗ NCT00171782 ↗ NCT04335786 ↗ NCT01912534 ↗ NCT00413049 ↗ NCT04859452 ↗ NCT00350168 ↗ NCT01353508 ↗ NCT03536598 ↗ NCT00809926 ↗ NCT00171106 ↗ NCT04707508 ↗ NCT03415906 ↗ NCT06344247 ↗ NCT03938389 ↗ NCT00927394 ↗ NCT00530595 ↗ NCT01406431 ↗ NCT00424801 ↗ NCT05155137 ↗ NCT03180593 ↗ NCT01095822 ↗ NCT00698646 ↗ NCT00487123 ↗ NCT05170061 ↗ NCT00385931 ↗ NCT00887588 ↗ NCT00409487 ↗ NCT00699192 ↗ NCT05387967 ↗ NCT05593575 ↗ NCT03012763 ↗ NCT00327587 ↗ NCT03066804 ↗ NCT05545059 ↗ NCT04394117 ↗ NCT05881720 ↗ NCT00171093 ↗ NCT00655330 ↗ NCT00878969 ↗ NCT05269615 ↗ NCT00239538 ↗ NCT00939588 ↗ NCT06053580 ↗ NCT00446511 ↗ NCT00171080 ↗ NCT00790946 ↗ NCT01918332 ↗ NCT00343499 ↗ NCT01819220 ↗ NCT02690974 ↗ NCT00902304 ↗ NCT07700875 ↗ NCT01071122 ↗ NCT00171067 ↗ NCT06536309 ↗ NCT02765594 ↗ NCT07331389 ↗ NCT07539298 ↗ NCT00294086 ↗ NCT03639480 ↗ NCT02058446 ↗ NCT06395194 ↗ NCT00394745 ↗ NCT00716950 ↗ NCT00171054 ↗ NCT00696436 ↗ NCT00415883 ↗ NCT01115972 ↗ NCT04623866 ↗ NCT00154271 ↗ NCT02299310 ↗ NCT01004237 ↗ NCT00171041 ↗ NCT00367562 ↗ NCT00185055 ↗ NCT00446524 ↗ NCT01400256 ↗ NCT02177396 ↗ NCT00171028 ↗ NCT02662894 ↗ NCT00351130 ↗ NCT00162955 ↗ NCT01281306 ↗ NCT00200694 ↗ NCT01167153 ↗ NCT05056727 ↗ NCT00433836 ↗ NCT00171015 ↗ NCT00599885 ↗ NCT04458285 ↗ NCT00437645 ↗ NCT03893526 ↗ NCT00171002 ↗ NCT00140790 ↗ NCT05681273 ↗ NCT00170989 ↗ NCT01508026 ↗ NCT00208767 ↗ NCT00170976 ↗ NCT00250562 ↗ NCT01001572 ↗ NCT01878201 ↗ NCT00170963 ↗ NCT03990480 ↗ NCT03309618 ↗ NCT00921570 ↗ NCT00416468 ↗ NCT00425373 ↗ NCT00241137 ↗ NCT01447485 ↗ NCT00311740 ↗ NCT00858299 ↗ NCT00657241 ↗ NCT02403349 ↗ NCT00426478 ↗ NCT03553810 ↗ NCT00170924 ↗ NCT00425997 ↗ NCT00550095 ↗ NCT00400777 ↗ NCT00353912 ↗ NCT07458880 ↗ NCT00396656 ↗ NCT00416728 ↗ NCT01850160 ↗ NCT00687973 ↗ NCT00460213 ↗ NCT00360178 ↗ NCT00666536 ↗ NCT02631031 ↗ NCT03432468 ↗ NCT00308425 ↗ NCT03988634 ↗ NCT00457483 ↗ NCT00839683 ↗ NCT04047940 ↗ NCT00171756 ↗ NCT02606279 ↗ NCT00982358 ↗ NCT00327145 ↗ NCT01764178 ↗ NCT00240448 ↗ NCT01129557 ↗ NCT00446563 ↗ NCT00367939 ↗ NCT06035978 ↗ NCT02687932 ↗ NCT01928628 ↗ NCT00549770 ↗ NCT00546754 ↗ NCT01917149 ↗ NCT03168568 ↗ NCT06487949 ↗ NCT06863987 ↗ NCT01415505 ↗ NCT00153023 ↗ NCT00687206 ↗ NCT01735890 ↗ NCT01252238 ↗ NCT00171535 ↗ NCT01681576 ↗ NCT00302705 ↗ NCT03005184 ↗ NCT01920711 ↗ NCT07491718 ↗ NCT01805804 ↗ NCT00661895 ↗ NCT07327749 ↗ NCT00295542 ↗ NCT01609959 ↗ NCT01541189 ↗ NCT02495324 ↗ NCT00457626 ↗ NCT03393377 ↗ NCT03279861 ↗ NCT00310778 ↗ NCT01609907 ↗ NCT04800081 ↗ NCT04055428 ↗ NCT06248112 ↗ NCT03532854 ↗ NCT04971720 ↗ NCT00241007 ↗ NCT05920005 ↗ NCT00518479 ↗ NCT04769778 ↗ NCT00407680 ↗ NCT00503152 ↗ NCT02242318 ↗ NCT03476616 ↗ NCT01241487 ↗ NCT04128891 ↗ NCT00171561 ↗ NCT00426348 ↗ NCT00280540 ↗ NCT03791723 ↗ NCT00170937 ↗ NCT00097786 ↗ NCT00591578 ↗ NCT05487261 ↗ NCT00304226 ↗ NCT00241072 ↗ NCT00171574 ↗ NCT00171600 ↗ NCT03508739 ↗ NCT00034840 ↗ NCT00241085 ↗ NCT00241098 ↗ NCT00241124 ↗ NCT00931710 ↗ NCT00241150 ↗ NCT00309257 ↗ NCT01340326 ↗ NCT01432106 ↗ NCT05528419 ↗ NCT00376272 ↗ NCT00589732 ↗ NCT01402843 ↗ NCT06930885 ↗ NCT03300427 ↗ NCT03552575 ↗ NCT00190580 ↗ NCT00273299 ↗ NCT00738972 ↗ NCT02815657 ↗ NCT02058823 ↗ NCT00548067 ↗ NCT05194111 ↗ NCT02572960 ↗ NCT02145104 ↗ NCT00874601 ↗ NCT02817217 ↗ NCT01672476 ↗ NCT00435162 ↗ NCT00413413 ↗ NCT07139405 ↗ NCT00922441 ↗ NCT00700271 ↗ NCT00494715 ↗ NCT04606563 ↗ NCT02816736 ↗ NCT06643819 ↗ NCT04687111 ↗ NCT06501651 ↗ NCT03315832 ↗ NCT05060588 ↗ NCT01365481 ↗
Known as	CGP 48933	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	D763	“1 D763(Valsartan 80 mg)” NCT06643819 ↗
Known as	D764	“1 D764(Valsartan 160 mg)” NCT06643819 ↗
Known as	Diovan	“The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day...” NCT00874601 ↗ 8 “Valsartan (Diovan), an FDA approved angiotensin-II receptor antagonist (blocker) clinically indicated for the treatment of essential hypertension” NCT01095822 ↗ “After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks.” NCT00130156 ↗ “Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months” NCT01129557 ↗ “MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan)” NCT00034840 ↗ “Drug: Diovan (Valsartan)” NCT00993109 ↗ “Valsartan (Diovan)” NCT04335786 ↗ NCT07547878 ↗ NCT01518855 ↗
Known as	Diovan (Valsartan)	“Diovan (Valsartan)” NCT01432106 ↗
Known as	Diovan is a brand name of Valsartan	“Diovan is a brand name of Valsartan” NCT00208767 ↗
Known as	NSC-758927	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Prexxartan	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	V= Valsartan = brand name : Diovan	“V= Valsartan = brand name : Diovan” NCT01918709 ↗
Known as	VAL	“OBJECTIVE: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ)...” PMID 23721363 ↗ Jul 2013 5 “To compare this ARB with another in the class, the authors studied the effects of AZL-M and valsartan (VAL) in 984 patients with primary hypertension in a randomized,...” PMID 21762358 ↗ Jun 2011 “treatment with sacubitril/valsartan (Sac/Val) was associated with greater reduction in NT-proBNP than valsartan (Val) alone in patients stabilized after an episode of worsening...” PMID 40268180 ↗ Apr 2025 “We compared an angiotensin receptor blocker (valsartan; VAL), a beta-blocker (nebivolol; NEB) and the combination of NEB/VAL” PMID 26116459 ↗ Mar 2015 “valsartan (VAL)/HCTZ 80/12.5 mg” PMID 18761785 ↗ Aug 2008 “valsartan (Val) 80 mg” PMID 18538118 ↗ Jun 2008
Known as	VAL489	“Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the...” NCT02924727 ↗ 3 “Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.” NCT04912167 ↗ “Valsartan (VAL489)” NCT01447485 ↗ NCT01617681 ↗
Known as	valsartan (Diovan)	“valsartan (Diovan)” NCT00000620 ↗
Known as	Valsartan component of agsav301	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of byvalson	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of copalia	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of copalia-hct	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of dafiro	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of dafiro-hct	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of diovan hct	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of entresto	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of exforge	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of exforge hct	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of imprida	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of imprida-hct	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartan component of valturna	ChEMBL registry synonym — accepted as the source's own label CHEMBL1069 ↗
Known as	Valsartin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00130156 ↗
Action	Inhibit	“angiotensin II receptor blocker (ARB), valsartan” PMID 24035165 ↗ Sep 2013 1 “Type-1 angiotensin II receptor antagonist” CHEMBL1069 ↗
Modality	Small molecule	— CHEMBL1069 ↗
Route	Oral	“Diovan® (Valsartan 160 mg p.o. Once Daily)” NCT00034840 ↗
Target	AGTR1	“Type-1 angiotensin II receptor antagonist” CHEMBL1069 ↗